


T-705 (Favipiravir)

Catalog No. A11590



T-705, a substituted pyrazine compound, has been found to exhibit potent anti-influenza virus activity in vitro and in vivo.

Our product Favipiravir is a raw chemical in Powder form for laboratory research use only. It is *NOT* a FDA approved medicine, and can NOT be used for any treatment or clinical trials on humans!

Your order will *NOT* be fulfilled unless academic or government institutes!

Product Citations

- JE Comer, .et al. Filovirus Virulence in Interferon α , β and γ Double Knockout Mice, and Treatment with Favipiravir, Viruses, 2019, Feb 3;11(2). pii: E137 PMID: 30717492 (<https://www.ncbi.nlm.nih.gov>

FREE SHIPPING

On Orders Over \$500

Accept payments online

Money back guarantee

Ships items quickly

Next-day delivery

Contact information



United States

Adooq Bioscience

Toll Free: (866) 930-6790

Fax: +1-323-606-8156

Email: sales@adooq.com

Adooq Quality Guarantee



/pubmed/30717492)

- Ma J, .et al. Enhancing the antiviral potency of ER α -glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo, Antiviral Res, 2018, Feb;150:112-122 [PMID: 29253498](#) (<https://www.ncbi.nlm.nih.gov/pubmed/29253498>)
- Ji-Ae Kim, .et al. Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models, Viruses, 2018, Feb; 10(2): 72 [PMID: 29425176](#) (<https://www.ncbi.nlm.nih.gov/pubmed/29425176>)
- Haejin Chun, .et al. Efficient antiviral co-delivery using polymersomes by controlling the surface density of cell-targeting groups for influenza A virus treatment, Polym Chem, 2018, 9: 2116-2123
- Baz M, .et al. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus, Viruses, 2018, Nov 3;10(11) [PMID: 30400276](#) (<https://www.ncbi.nlm.nih.gov/pubmed/30400276>)
- Sehee Park, .et al. Combination Effects of Peramivir and Favipiravir against Oseltamivir-Resistant 2009 Pandemic Influenza A(H1N1) Infection in Mice, PLoS One., 2014, 9(7): e101325 [PMID: 24992479](#) (<https://www.ncbi.nlm.nih.gov/pubmed/24992479>)



We
promise all
products
perform as
described.

Technical details



CATALOG NUM	A11590
M. WT	157.1
FORMULA	C ₅ H ₄ FN ₃ O ₂
PURITY	>98%
STORAGE	at -20°C 3 years Powder
CAS NO.	259793-96-9
SYNONYMS	T705, T 705
SMILES	<chem>Cl=C(N=C(C(=O)N)C(=O)N)F</chem>

Biological Activity



T-705, a substituted pyrazine compound, has been found to exhibit potent anti-influenza virus activity in vitro and in vivo.

Our product Favipiravir is a raw chemical in Powder form for laboratory research use only. It is *NOT* a FDA approved medicine, and can NOT be used for any treatment or clinical trials on humans!

Your order will *NOT* be fulfilled unless academic or government institutes!

Targets

RNA-dependent RNA polymerase				

Preparing Stock Solutions



Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	63.65 mL	318.27 mL	636.54 mL
0.5 mM	12.73 mL	63.65 mL	127.31 mL
1 mM	6.37 mL	31.83 mL	63.65 mL
5 mM	1.27 mL	6.37 mL	12.73 mL

*The above data is based on the product molecular weight 157.1.

Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.